Evidence map›Paper›PMID 36384809›Full record

ArticleAlzheimer's research & therapy2022

Multi-platform proteomic analysis of Alzheimer's disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome.

Eric B Dammer, Lingyan Ping, Duc M Duong, Erica S Modeste, Nicholas T Seyfried, James J Lah, Allan I Levey, Erik C B Johnson

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers.

0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed
20.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

134 citing papers in PubMed, 181 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  8. Article
  9. Article
  10. GPIHBP1 on oligodendrocytes binds lipoprotein lipase within the human brain.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

74 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Eric B DammerGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Whitehead Building-Suite 505C, 615 Michael Street, Atlanta, GA, 30322, USA.
Lingyan PingGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Whitehead Building-Suite 505C, 615 Michael Street, Atlanta, GA, 30322, USA.
Duc M DuongGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Whitehead Building-Suite 505C, 615 Michael Street, Atlanta, GA, 30322, USA.
Erica S ModesteGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Whitehead Building-Suite 505C, 615 Michael Street, Atlanta, GA, 30322, USA.
Nicholas T SeyfriedGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Whitehead Building-Suite 505C, 615 Michael Street, Atlanta, GA, 30322, USA.
James J LahGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Whitehead Building-Suite 505C, 615 Michael Street, Atlanta, GA, 30322, USA.
Allan I LeveyGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Whitehead Building-Suite 505C, 615 Michael Street, Atlanta, GA, 30322, USA.
Erik C B JohnsonGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Whitehead Building-Suite 505C, 615 Michael Street, Atlanta, GA, 30322, USA. erik.c.b.johnson@emory.edu.
Emory University · US

Funding

TREAT AD Structural Biology CoreU54AG065187 · NIA · EMORY UNIVERSITY · PI Gregory W Carter, ALLAN I LEVEY · 2019 to 2026
$69.7M
The Goizueta Alzheimer's Disease Research CenterP30AG066511 · NIA · EMORY UNIVERSITY · PI Monica Willis Parker · 2020 to 2026
$29.0M
Brain Proteomic Network Analysis to Elucidate Mechanisms and Biomarkers for Alzheimer's DiseaseK08AG068604 · NIA · EMORY UNIVERSITY · PI JOHNSON, ERIK C.B. · 2020 to 2024
$762k
NIA NIH HHS K08 AG068604NIA NIH HHS P30 AG066511NIA NIH HHS U54 AG065187
6 · The paper itself

Abstract

Robust and accessible biomarkers that can capture the heterogeneity of Alzheimer's disease and its diverse pathological processes are urgently needed. Here, we undertook an investigation of Alzheimer's disease cerebrospinal fluid (CSF) and plasma from the same subjects (n=18 control, n=18 AD) using three different proteomic platforms-SomaLogic SomaScan, Olink proximity extension assay, and tandem mass tag-based mass spectrometry-to assess which protein markers in these two biofluids may serve as reliable biomarkers of AD pathophysiology observed from unbiased brain proteomics studies. Median correlation of overlapping protein measurements across platforms in CSF (r~0.7) and plasma (r~0.6) was good, with more variability in plasma. The SomaScan technology provided the most measurements in plasma. Surprisingly, many proteins altered in AD CSF were found to be altered in the opposite direction in plasma, including important members of AD brain co-expression modules. An exception was SMOC1, a key member of the brain matrisome module associated with amyloid-β deposition in AD, which was found to be elevated in both CSF and plasma. Protein co-expression analysis on greater than 7000 protein measurements in CSF and 9500 protein measurements in plasma across all proteomic platforms revealed strong changes in modules related to autophagy, ubiquitination, and sugar metabolism in CSF, and endocytosis and the matrisome in plasma. Cross-platform and cross-biofluid proteomics represents a promising approach for AD biomarker development.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersHumansProteomicsProteostasisAmyloid beta-PeptidesBiomarkers

Identifiers

PMID36384809
PMCPMC9670630
OpenAlexW4309511017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.